Locoregional IL-2 therapy in the treatment of colon cancer. Cell-induced lesions of a murine model

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 985-989

  Caporale, A ^a   Brescia, A ^a   Galati, G ^a   Castelli, M ^b   Saputo, S ^a   Terrenato, I ^b   Cucina, A ^a   Liverani, A ^a   Gasparrini, M ^a   Ciardi, A ^a   Scarpini, M ^a   Cosenza, Umile Michele ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Regina Elena Cancer Institute ^*  (Italy)

Author keywords

Colon cancer; IL 2; Locoregional immunotherapy

Indexed keywords

ALBUMIN; RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER LOCALIZATION; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; INOCULATION; LIVER CELL DAMAGE; MITOSIS INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL; SPLEEN WEIGHT;

ANIMALS; COLORECTAL NEOPLASMS; INTERLEUKIN-2; LIVER NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; RATS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34247162394     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Perrin P, Cassagnau E, Burg C, Patry Y, Vavasseur F, Harb J, Le Pendu J, Douillard JY, Galmiche JP, Bornet F and Meflah K: An interleukin 2/sodium butyrate combination as immunotherapy for rat coloncancer peritoneal carcinomatosis. Gastroenterology 107(6): 1697-1708, 1994.
2. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seip Ca, Simpson CG and White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2alone. N Engl J Med 316(15): 889-897, 1987.
3. Urba WJ, Clark JW, Steis RG, Bookman MA, Smith JW 2nd, Beckner S, Maluish AE, Rossio JL, Rager H, Ortaldo JR and Ongo DL: Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations. J Natl Cancer Inst 81(8): 602-611, 1989.
4. Balemans LT, Mattijssen V, Steerenberg PA, Van Driel BE, De Mulder PH and and Den Otter W: Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity. Cancer Immunol Immunother 37(1): 7-14, 1993.
5. Hihara J, Yamaguchi Y, Minami K, Noma K and Toge T: Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion. Anticancer Res 19(2A): 1077-1084, 1999.
6. Yamaguchi Y, Satoh Y, Miyahara E, Noma K, Funakoshi M, Takashima I, Sawamura A and Toge T: Locoregional immunotherapy of malignant ascites by intraperitoneal-administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res 15(5B): 2201-2206, 1995.
7. Den Otter W, Ziekmann PGPM, Koten JW and Lygidakis NJ: suggestions/requirements for a protocol to treat colorectal cancer with IL-2. Hepatogastroenterology 48(37): Letter to Editor, 2001.
8. Kusnierczyk H, Pajtasz-Piasecka E, Koten JW, Bijleveld C, Krawczyk K and Den Otter W: Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol Immunother 53(5): 445-452, 2004.
9. Romano F, Cesana G, Berselli M, Gaia Piacentini M, Caprotti R, Bovo G and Uggeri FR: Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients. J Surg Oncol 88(4): 240-247, 2004.
10. Yamaguchi Y, Miyahara E, Ohshita A, Kawabuchi Y, Ohta K, Shimizu K, Minami K, Hihara J, Sawamura A and Toge T: Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes. Br J Cancer 89(10): 1876-1884, 2003.
11. Krastev Z, Koltchakov V, Tomova R, Deredjian S, Alexiev A, Popov D, Tomov B, Koten JW, Jacobs J and Den Otter W: Locoregional IL-2 low dose applications for gastrointestinal tumors. World J Gastroenterol 11(35): 5525-5529, 2005.
12. Karube H, Masuda H, Hayashi S, Ishii Y and Nemoto N: Fatty liver suppressed the angiogenesis in liver metastatic lesions. Hepatogastroenterology 47(36): 1541-1545, 2000.
13. Jacquet P and Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Peritoneal carcinomatosis: principles of management. Sugarbaker PH (ed). Boston, Kluwer Academic, pp. 359-374, 1996.
14. Boring CC, Squires TS and Tong T: Cancer Statistics. Cancer J Clin 42: 19-38, 1992.
15. Moertel CG: Accomplishments in surgical adjuvant therapy for large bowel cancer. Cancer 70(5 Suppl): 1364-1371, 1992.
16. Huland E, Heinzer H and Huland H: Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Anticancer Res 19(4A): 2679-2683, 1999.
17. Beatty JD: Immunotherapy of colorectal cancer. Cancer 70(5 Suppl): 1425-1433, 1992.
18. Gazit Z, Weiss DW, Shouval D, Yechezkeli M, Schirrmacher V, Notter M, Walter J and Kedar E: Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines. Cancer Immunol Immunother 35(2): 135-144, 1992.
19. Jacobs JJ, Sparendam D and Den Otter W: Local interleukin 2 therapy is most effective against cancer when injected intratumourally. Cancer Immunol Immunother 54(7): 647-654, 2005.
20. Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten JW and Den Otter W: A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother 50(4): 226-227, 2001.
21. Den Otter W, Balemans L, Battermann JJ, Bernsen MR, Cadee JA, Dobrowolski Z, Everse LA, Fiszer-Maliszewska L, Gavhumende R, De Groot JW, De Groot K, Hennink WE, Hill FW, Jurgenliemp-Schulz I, Klein WR, Koten JW, Maas RA, Steerenberg P, Stewart R and Zembala M: Local low-dose IL-2 therapy. Hepatogastroenterology 46(Suppl 1): 1280-1286, 1999.
22. Baselmans AH, Koten JW, Battermann JJ, Van Dijk JE and Den Otter W: The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 51(9): 492-498, 2002.
23. Van Es RJ, Baselmans AH, Koten JW, Van Dijk JE, Koole R and Den Otter W: Perilesional IL-2 treatment of a VX2 head-and-neck cancer model can induce a systemic anti-tumour activity. Anticancer Res 20(6B): 4163-4170, 2000.